Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018

Climate Change
---RFI from House Select Committee on the Climate Crisis

EPA Regulations on Biotechnology
---EPA Plant Biotech Regulatory Policy
---H.R.4373: Engineering Biology Research and Development Act

Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018

Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---Korea Biotechnology Regulations
---International Consistency of Regulation for Gene Edited Products

Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020

Funding for the USDA
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Provisions on GE Salmon Labeling

Genetically Engineered (GE) Plants
---EPA Regulatory Approach to Gene Editing
---FDA Proposed Guidance on Gene Editing

The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions

US-China Trade Negotiations
---Ag Biotech Provisions

USDA/APHIS Agricultural Biotechnology Regulations
---USDA Part 340 Revision

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Provisions on GE Salmon Labeling

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Agriculture - Dept of (USDA), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020

Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

Funding for Biofuels
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052/S.2580: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3163/S.2520: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Biorefineries
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for FDA
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Aderholt Full Committee Amendment on Germline Editing

Funding for Health Resources and Services Administration (HRSA)
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---Vaccine Injury Compensation Program (VICP)

Funding for National Institutes of Health
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)

Funding for Renewable Chemicals/Bio-based Products
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

Funding for the USDA
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Climate Change
---RFI from House Select Committee on the Climate Crisis

Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018

Funding for Renewable Chemicals/Bio-based Products
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Implementation of the Agriculture Improvement Act of 2018
---Investment Tax Credit
---Production Tax Credit

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Bayh-Dole Act/Tech Transfer
---Domestic Manufacturing Requirement
---March-In Rights

Compulsory Licensing
---H.R.465/S.102: Prescription Drug Price Relief Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019

Drug Patenting
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019

Intellectual Property International Enforcement
---China
---Colombia
---India
---Malaysia
---Saudi Arabia

Inter Partes Review
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019
---S.440: Preserving Access to Cost Effective Drugs Act (PACED) Act of 2019

Patent Reform
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019

Patenting of Biological Inventions
---Argentina Biotech Patentability Guidelines
---DNA Patenting and Licensing
---PTO Examination Guidelines
---Section 101 Modernization

The United States-Mexico-Canada Agreement
---IP Provisions

US-China Trade Negotiations
---IP Provisions

US-Japan Trade Agreement
---IP Provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019

Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Provisions on GE Salmon Labeling

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Agriculture - Dept of (USDA), Natl Economic Council (NEC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Extenders
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---Implementation of the Agriculture Improvement Act of 2018
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.

Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018

Biorefineries (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018

Climate Change
---RFI from House Select Committee on the Climate Crisis

Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018

Funding for Biofuels
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052/S.2580: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3163/S.2520: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Biorefineries
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Renewable Fuel Standard (RFS)
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---RFS Reform
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, Natl Economic Council (NEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Extenders
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---Implementation of the Agriculture Improvement Act of 2018
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.

Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018

Biorefineries (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018

Climate Change
---RFI from House Select Committee on the Climate Crisis

Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018

Funding for Biofuels
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052/S.2580: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3163/S.2520: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Biorefineries
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Renewable Fuel Standard (RFS)
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---RFS Reform
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

340B Drug Discount Program
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)

Antibiotic & Diagnostic Tax Credit

Biodefense Research, Development and Procurement Issues (Non-funding)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Implementation of Medical Countermeasures Innovation Act
---Implementation of the 21st Century Cures Act of 2016
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019
---National Biodefense Strategy
---Pandemic Influenza Preparedness
---Tropical Disease Priority Review Voucher (PRV) Program

Biosimilars
---Access to Samples for Testing
---Biosimilar Copay Elimination
---Brazil Biologics Regulations
---Canada Biologics Regulations
---Coding
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
---India Biologics Regulations
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---Reimbursement
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019

Climate Change
---RFI from House Select Committee on the Climate Crisis

Comparative Effectiveness Research Initiatives
---Reauthorization of Patient-Centered Outcomes Research Institute

21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

Diagnostics and Personalized Medicine Regulation and Oversight
---VALID Act (Discussion Draft House)

Drug Evaluation and Review
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---FDA Review of CBD-Based Drugs
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Innovation Incentives
---Patient-Focused Drug Development
---Priority Review Voucher Programs
---Regulatory Reform & Modernization
---S.660: Efficiency and Transparency in Petitions Act
---Use of Real-World Evidence

Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---S.Con.Res25: The FY 2018 Budget Resolution

Drug Patenting
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019

Drug Pricing
---CMMI Authority
---General
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.965/S.340: CREATES Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2069/S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
---H.R.2113: Prescription Drug STAR Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.2387: STOP GAMES Act of 2019
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Pricing Transparency
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.2911:Seniors Prescription Drug Relief Act of 2019

Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

Funding for FDA
---Aderholt Full Committee Amendment on Germline Editing
---Biotechnology and Agriculture Trade Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020

Funding for Health Resources and Services Administration (HRSA)
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---Vaccine Injury Compensation Program (VICP)

Funding for National Institutes of Health
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills

Generic Drug Entry
---Access to Samples for Testing
---Generic Drug Application Review Reforms
---H.R.297: Increasing Competition in Pharmaceuticals Act of 2019
---H.R.749: Lower Drug Costs Through Competition Act of 2018
---H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.2374/S.1224: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act of 2019
---Incentives for Generic Drug Entry
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.660: Efficiency and Transparency in Petitions Act

International Biosecurity Policies

Medicaid
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

Orphan Drug Issues
---Tax Credit

Reimbursement and Coverage of Innovative Products
---Administration Rebate Rule
---CMMI Authority
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Step Therapy
---Value-based Contracting and Communications

The United States-Mexico-Canada Agreement
---IP Provisions

US-China Trade Negotiations
---IP Provisions

US-Japan Trade Agreement
---IP Provisions

Vaccines and Infectious Diseases
---Executive Order on Modernizing Influenza Vaccines
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
---S.1872: Protecting Seniors through Immunizations Act of 2019
---Vaccine and Anti-Microbial Resistance Product Development and Incentives

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), White House Office, U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Patent & Trademark Office (PTO), State - Dept of (DOS), Council of Economic Advisers (CEA), Food & Drug Administration (FDA), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-funding)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Implementation of Medical Countermeasures Innovation Act
---Implementation of the 21st Century Cures Act of 2016
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019
---National Biodefense Strategy
---Pandemic Influenza Preparedness
---Tropical Disease Priority Review Voucher (PRV) Program

Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-funding)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Implementation of Medical Countermeasures Innovation Act
---Implementation of the 21st Century Cures Act of 2016
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019
---National Biodefense Strategy
---Pandemic Influenza Preparedness
---Tropical Disease Priority Review Voucher (PRV) Program

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

Funding for National Institutes of Health
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

340B Drug Discount Program
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)

Biosimilars
---Biosimilar Copay Elimination
---Coding
---Reimbursement

21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

Drug Pricing
---CMMI Authority
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.2911:Seniors Prescription Drug Relief Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019

Medicaid
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

Reimbursement and Coverage of Innovative Products
---Administration Rebate Rule
---CMMI Authority
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Step Therapy
---Value-based Contracting and Communications

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Council of Economic Advisers (CEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---Encouraging Employee Ownership Act
---SEC Rule 701
---SEC Small Business Forum
---Small Business Capital Formation Enhancement Act

Proxy Advisory Services
---Corporate Governance Reform and Transparency
---Impact of Policies on Small Public Companies

Sarbanes Oxley Section 404 (b)
---Reintroduction of the Fostering Innovation Act in the House of Representatives
---S.452: Fostering Innovation Act of 2019
---Small Issuer Exemption

Short Selling Transparency

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Antibiotic & Diagnostic Tax Credit

Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Extenders
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019

Capital Formation Investment Incentives
---Introduction of the American Innovation Act in the Senate
---Reform of Net Operating Loss Rules
---Reintroduction of the American Innovation Act in the House

Orphan Drug Issues
---Tax Credit

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Investment Tax Credit
---Production Tax Credit

Research & Development Tax Credit Reforms
---Expensing of R&D Expenditures
---R&D Payroll Credit

Vaccine Injury Compensation Tax
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Committee on Foreign Investment in the United States (CFIUS)
---Foreign Investment Risk Review Modernization Act (FIRRMA) Implementation

Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019

Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---International Consistency of Regulation for Gene Edited Products
---Korea Biotechnology Regulations

Intellectual Property International Enforcement
---China
---Colombia
---India
---Malaysia
---Saudi Arabia

The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions
---IP Provisions

US-China Trade Negotiations
---Ag Biotech Provisions
---IP Provisions

US-Japan Trade Agreement
---IP Provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Treasury - Dept of, Agriculture - Dept of (USDA), Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SCI

16. Specific lobbying issues

Engineering Biology
---H.R.4373: Engineering Biology Research and Development Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes